Abstract:<h3>Purpose/Objective(s)</h3> To retrospectively investigate the efficacy and prognostic factors of multiple/all lesions stereotactic ablative radiotherapy (SABR) for oligometastatic renal carcinoma (RCC). <h3>Materials/Methods</h3> The present study retrospectively reviewed thirty-five patients with oligometastatic RCC (1-5 metastases) who received stereotactic ablative radiotherapy (SABR) between April 2015 and December 2020. All patients were treated with SABR (6-10Gy/f, 5 or 10f) or partial-SABR boost to the lesions (40-60Gy/20-25f with tumor center boosted with 6-8Gy/f, 3-5f) for bulky tumors or tumors adjacent to critical organs. 31 patients underwent systematic therapy. Daily CBCT image guidance was used for each patient. Thirty-one patients underwent targeted therapy or targeted plus immunotherapy. <h3>Results</h3> 35 patients with 8 primary lesions and 92 metastatic lesions were included in this study. The median follow-up time was 17.0 months (range 6.1-75.4 months). The average age of all patients was 63 years. Clear cell renal cell carcinoma accounted for 77.1% of all RCC cases. Four patients (11.4%) had sarcomatoid differentiation. 78.5% of the patients had an intermediate or poor IMDC risk. Surgery on primary or metastatic sites was previously performed in 85.7% patients. The median time interval from first distant metastasis radiation therapy (DM-RT) was 7.2 months (range 0 to 50.2 months). Of the patients, 19 were treated for all primary and/or metastatic lesions. Forty percent of the patients received RT before tyrosine kinase inhibitor (TKI) failure. Of the 48 irradiated lesions, 15 received SABR, and 33 received partial-SABR. The local control rate (LRFS), progression-free survival rate (PFS) and overall survival rate (OS) of the whole group at 1 and 3 years were 78% and 78% and 41.8% and 27.9% and 78.3% and 48.2%, respectively. Univariate analysis showed that OS benefit were found in patients who received radiation before tyrosine kinase inhibitor (TKI) failure (p = 0.006) and a short time interval (<6 months) to radiotherapy (p = 0.046). Similar results were also found in PFS in patients who received radiation before TKI failure (p = 0.049) or within 8 months (p = 0.047). There were certain differences in PFS (P = 0.033) between patients receiving radiotherapy to all lesion and those to selected tumors. In multivariate analysis, OS benefits were found in patients who received SABR before TKI failure (p = 0.028). There were certain differences in PFS (P =0.033) between patients receiving radiotherapy to all lesion and those to selected tumors. In multivariate analysis, OS benefits were found in patients who received radiotherapy before TKI failure (p = 0.028), but there was no significant difference in relation to other characters due to the small sample size. <h3>Conclusion</h3> Early use of SABR and all sites irradiation may improve survival. Partial-SABR for bulky lesions close to critical organs could be safely and effectively applied under certain circumstances.

Stereotactic ablative radiotherapy for colorectal cancer liver metastasis

110P Analysis for Stereotactic Body Radiotherapy (SBRT) Effect for Colorectal Liver Metastases

Analysis of therapeutic effect and influencing factors of radiofrequency ablation for colorectal cancer liver metastases

Comparison of Percutaneous Radiofrequency Ablation for Subcapsular and Non-Subcapsular Colorectal Cancer Liver Metastases

Outcomes of Targeted Therapy Plus Immunotherapy and High-Dose Stereotactic Ablative Body Radiotherapy (SABR) for Metastatic Renal Cell Cancer Patients.

Stereotactic body radiation therapy for colorectal cancer liver metastases

Progress on stereotactic body radiation therapy for liver metastases

Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.

Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer

Recent Advances in the Comprehensive Treatment of Colorectal Liver Metastases

Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases

Surgical treatment of colorectal cancer liver metastasis

Efficacy and Safety Outcomes of Using Stereotactic Ablative Radiotherapy for Oligometastatic Lesions from Colorectal Cancer

Consideration of Therapy for Colorectal Cancer with Synchronous Unresectable Liver Metastasis

Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines

Outcomes of Multiple/All lesions Stereotactic Ablative Radiation Therapy (SABR) for Oligo-Metastatic Renal Cancer

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions

Radiotherapy combined with cytokine-induced killer cell therapy for liver metastasis from rectal cancer: A case report

Percutaneous Microwave Ablation Combined with Synchronous Transcatheter Arterial Chemoembolization for the Treatment of Colorectal Liver Metastases: Results from A Follow-Up Cohort

Advances in the Precision Treatment of Colorectal Liver Metastases

[Interventional therapy of colorectal liver metastasis]